138 related articles for article (PubMed ID: 12392705)
21. Selective Neutral pH Inhibitor of Cathepsin B Designed Based on Cleavage Preferences at Cytosolic and Lysosomal pH Conditions.
Yoon MC; Solania A; Jiang Z; Christy MP; Podvin S; Mosier C; Lietz CB; Ito G; Gerwick WH; Wolan DW; Hook G; O'Donoghue AJ; Hook V
ACS Chem Biol; 2021 Sep; 16(9):1628-1643. PubMed ID: 34416110
[TBL] [Abstract][Full Text] [Related]
22. Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors.
Turk D; Podobnik M; Popovic T; Katunuma N; Bode W; Huber R; Turk V
Biochemistry; 1995 Apr; 34(14):4791-7. PubMed ID: 7718586
[TBL] [Abstract][Full Text] [Related]
23. Crystal structure of NS-134 in complex with bovine cathepsin B: a two-headed epoxysuccinyl inhibitor extends along the entire active-site cleft.
Stern I; Schaschke N; Moroder L; Turk D
Biochem J; 2004 Jul; 381(Pt 2):511-7. PubMed ID: 15084146
[TBL] [Abstract][Full Text] [Related]
24. Cathepsin B: Active site mapping with peptidic substrates and inhibitors.
Schmitz J; Gilberg E; Löser R; Bajorath J; Bartz U; Gütschow M
Bioorg Med Chem; 2019 Jan; 27(1):1-15. PubMed ID: 30473362
[TBL] [Abstract][Full Text] [Related]
25. Expression and alteration of the S2 subsite of the Leishmania major cathepsin B-like cysteine protease.
Chan VJ; Selzer PM; McKerrow JH; Sakanari JA
Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):113-7. PubMed ID: 10229665
[TBL] [Abstract][Full Text] [Related]
26. Structure of rat procathepsin B: model for inhibition of cysteine protease activity by the proregion.
Cygler M; Sivaraman J; Grochulski P; Coulombe R; Storer AC; Mort JS
Structure; 1996 Apr; 4(4):405-16. PubMed ID: 8740363
[TBL] [Abstract][Full Text] [Related]
27. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives.
Matsumoto K; Mizoue K; Kitamura K; Tse WC; Huber CP; Ishida T
Biopolymers; 1999; 51(1):99-107. PubMed ID: 10380357
[TBL] [Abstract][Full Text] [Related]
28. Role of the occluding loop in cathepsin B activity.
Illy C; Quraishi O; Wang J; Purisima E; Vernet T; Mort JS
J Biol Chem; 1997 Jan; 272(2):1197-202. PubMed ID: 8995421
[TBL] [Abstract][Full Text] [Related]
29. The baculovirus cysteine protease has a cathepsin B-like S2-subsite specificity.
Brömme D; Okamoto K
Biol Chem Hoppe Seyler; 1995 Oct; 376(10):611-5. PubMed ID: 8590630
[TBL] [Abstract][Full Text] [Related]
30. Effects of selective inhibition of cathepsin B and general inhibition of cysteine proteinases on lysosomal proteolysis in rat liver in vivo and in vitro.
Ohshita T; Nikawa T; Towatari T; Katunuma N
Eur J Biochem; 1992 Oct; 209(1):223-31. PubMed ID: 1382984
[TBL] [Abstract][Full Text] [Related]
31. Cathepsin B fraction active at physiological pH of 7.5 is of prognostic significance in squamous cell carcinoma of human lung.
Werle B; Jülke B; Lah T; Spiess E; Ebert W
Br J Cancer; 1997; 75(8):1137-43. PubMed ID: 9099961
[TBL] [Abstract][Full Text] [Related]
32. Effect of the selective and non-selective cysteine protease inhibitors on the intracellular processing of interleukin 6 by HEPG2 cells.
Peppard JV; Knap AK
In Vitro Cell Dev Biol Anim; 1999 Sep; 35(8):459-64. PubMed ID: 10501085
[TBL] [Abstract][Full Text] [Related]
33. Residue-specific annotation of disorder-to-order transition and cathepsin inhibition of a propeptide-like crammer from D. melanogaster.
Tseng TS; Cheng CS; Hsu ST; Shih MF; He PL; Lyu PC
PLoS One; 2013; 8(1):e54187. PubMed ID: 23349821
[TBL] [Abstract][Full Text] [Related]
34. A double-headed cathepsin B inhibitor devoid of warhead.
Schenker P; Alfarano P; Kolb P; Caflisch A; Baici A
Protein Sci; 2008 Dec; 17(12):2145-55. PubMed ID: 18796695
[TBL] [Abstract][Full Text] [Related]
35. Crystal structure of human osteoclast cathepsin K complex with E-64.
Zhao B; Janson CA; Amegadzie BY; D'Alessio K; Griffin C; Hanning CR; Jones C; Kurdyla J; McQueney M; Qiu X; Smith WW; Abdel-Meguid SS
Nat Struct Biol; 1997 Feb; 4(2):109-11. PubMed ID: 9033588
[No Abstract] [Full Text] [Related]
36. 1,2,4-thiadiazole: a novel Cathepsin B inhibitor.
Leung-Toung R; Wodzinska J; Li W; Lowrie J; Kukreja R; Desilets D; Karimian K; Tam TF
Bioorg Med Chem; 2003 Dec; 11(24):5529-37. PubMed ID: 14642597
[TBL] [Abstract][Full Text] [Related]
37. Crystal structures of recombinant rat cathepsin B and a cathepsin B-inhibitor complex. Implications for structure-based inhibitor design.
Jia Z; Hasnain S; Hirama T; Lee X; Mort JS; To R; Huber CP
J Biol Chem; 1995 Mar; 270(10):5527-33. PubMed ID: 7890671
[TBL] [Abstract][Full Text] [Related]
38. Optimization of peptidyl allyl sulfones as clan CA cysteine protease inhibitors.
Fennell BD; Warren JM; Chung KK; Main HL; Arend AB; Tochowicz A; Götz MG
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):468-78. PubMed ID: 22380780
[TBL] [Abstract][Full Text] [Related]
39. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi.
Lalmanach G; Mayer R; Serveau C; Scharfstein J; Gauthier F
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):395-9. PubMed ID: 8809025
[TBL] [Abstract][Full Text] [Related]
40. The crystal structure of human cathepsin L complexed with E-64.
Fujishima A; Imai Y; Nomura T; Fujisawa Y; Yamamoto Y; Sugawara T
FEBS Lett; 1997 Apr; 407(1):47-50. PubMed ID: 9141479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
